Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7MW4911 in advanced solid tumors
NCT07265622Phase 2Recruiting
- Sponsor
- Mabwell
- Start
- Nov 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 7MW4911 in solid tumor, sponsored by Mabwell. Started Nov 2025; status: recruiting.
02
Drugs
7MW4911
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07265622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07265622.